Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae in Japan.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, American Society for Microbiology
    • Subject Terms:
    • Abstract:
      IMP-type carbapenemase, found in various Gram-negative bacteria, has been increasingly detected worldwide. We aimed to study the outcomes and risk factors for acquisition of IMP-type carbapenemase-producing carbapenem-resistant Enterobacteriaceae (IMP-CRE), as this has not been evaluated in detail. We conducted a matched case-case-control study of patients from whom IMP-CRE isolates were obtained. All patients who tested positive for IMP-CRE were included; they were matched with patients with carbapenem-susceptible Enterobacteriaceae (CSE) and with controls at a ratio of 1:1:2. The risk factors for acquisition for the CRE and CSE groups and mortality rates, which were calculated using multivariate logistic regression models with weighting according to the inverse probability of propensity scores, were compared. In total, 192 patients (96 patients each in the CRE and CSE groups, with 130 Enterobacter cloacae isolates and 62 Klebsiella sp. isolates) were included. The IMP-11 type was present in 43 patients, IMP-1 in 33, and IMP-60 and IMP-66 in 1 each; 31 patients with CRE (32.3%) and 34 with CSE (35.4%) developed infections. Multivariate analysis identified the following independent risk factors: gastrostomy, history of intravenous therapy or hemodialysis, and previous exposure to broad-spectrum β-lactam antibiotics, including penicillin with β-lactamase inhibitors, cephalosporins, and carbapenems. In propensity score-adjusted analysis, mortality rates for the CRE and CSE groups were similar (15.0% and 19.5%, respectively). We found that IMP-CRE may not contribute to worsened clinical outcomes, compared to CSE, and gastrostomy, previous intravenous therapy, hemodialysis, and broad-spectrum antimicrobial exposure were identified as risk factors for CRE isolation. Fluoroquinolone and aminoglycosides are potentially useful antibiotics for IMP-CRE infections.
      (Copyright © 2021 American Society for Microbiology.)
    • References:
      J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36. (PMID: 28375512)
      Ann Clin Microbiol Antimicrob. 2018 Mar 23;17(1):13. (PMID: 29571291)
      Clin Microbiol Infect. 2014 Sep;20(9):831-8. (PMID: 24766097)
      Eur J Clin Microbiol Infect Dis. 2013 Mar;32(3):345-52. (PMID: 23001510)
      Sci Rep. 2017 Jul 27;7(1):6722. (PMID: 28751669)
      Clin Microbiol Rev. 2012 Oct;25(4):682-707. (PMID: 23034326)
      J Glob Antimicrob Resist. 2017 Dec;11:10-16. (PMID: 28743652)
      Infect Control Hosp Epidemiol. 2009 Dec;30(12):1180-5. (PMID: 19860564)
      J Infect Chemother. 2018 Sep;24(9):769-772. (PMID: 29656900)
      J Infect. 2018 May;76(5):438-448. (PMID: 29477802)
      Antimicrob Resist Infect Control. 2013 Dec 18;2(1):35. (PMID: 24345195)
      Clin Microbiol Infect. 2012 Jan;18(1):54-60. (PMID: 21722257)
      Antimicrob Agents Chemother. 2014;58(4):2322-8. (PMID: 24514083)
      Emerg Infect Dis. 2011 Oct;17(10):1791-8. (PMID: 22000347)
      J Clin Microbiol. 2003 Dec;41(12):5407-13. (PMID: 14662918)
      J Clin Microbiol. 2011 Dec;49(12):4239-45. (PMID: 21998425)
      J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716)
      J Antimicrob Chemother. 2016 Sep;71(9):2577-85. (PMID: 27197663)
      J Microbiol Methods. 2011 Dec;87(3):330-7. (PMID: 21986031)
      Lancet Infect Dis. 2011 May;11(5):381-93. (PMID: 21530894)
      Infect Control Hosp Epidemiol. 2005 Apr;26(4):346-51. (PMID: 15865269)
      J Hosp Infect. 2017 Nov;97(3):212-217. (PMID: 28736270)
      Antimicrob Agents Chemother. 2014 Jun;58(6):3441-50. (PMID: 24709261)
      Clin Infect Dis. 2017 Feb 1;64(3):257-264. (PMID: 28013264)
      Eur J Clin Microbiol Infect Dis. 2016 Mar;35(3):379-85. (PMID: 26740321)
      Ann Clin Microbiol Antimicrob. 2017 Jun 19;16(1):42. (PMID: 28629366)
      J Hosp Infect. 2017 Jun;96(2):111-115. (PMID: 28389093)
      J Antimicrob Chemother. 2007 Dec;60(6):1375-9. (PMID: 17913719)
      J Infect Chemother. 2019 Apr;25(4):240-246. (PMID: 30611637)
    • Contributed Indexing:
      Keywords: Enterobacteriaceae; IMP; carbapenem resistance; clinical outcomes; propensity score
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Bacterial Proteins)
      EC 3.5.2.6 (beta-Lactamases)
      EC 3.5.2.6 (carbapenemase)
      0 (Carbapenems)
    • Publication Date:
      Date Created: 20201201 Date Completed: 20221230 Latest Revision: 20221230
    • Publication Date:
      20240105
    • Accession Number:
      PMC8092526
    • Accession Number:
      10.1128/AAC.01483-20
    • Accession Number:
      33257451